Biodistribution of 111in-DTPA-D-Phe1-octreotide in tumor-bearing nude mice: influence of amount injected and route of administration

Nucl Med Biol. 2003 Apr;30(3):253-60. doi: 10.1016/s0969-8051(02)00417-1.

Abstract

In nude mice carrying the human carcionoid GOT1 different amounts of (111)In-DTPA-Phe(1)-octreotide and routes of administration were studied in relation to uptake in tumor and normal organs. The relative organ uptake varied with given amount; highest in tumor after 0.1 and 1 microg and lowest in muscle, heart and blood after 0.1 microg. The uptake decreased in lungs and spleen with higher amounts of (111)In-DTPA-Phe(1)-octreotide. In all organs studied the tumor-to-normal-tissue activity concentration ratio was maximal at 0.1 and 1 microg, but route of administration influenced the uptake only little.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Carcinoid Tumor / metabolism*
  • Humans
  • Injections, Intraperitoneal
  • Injections, Intravenous
  • Injections, Subcutaneous
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Octreotide / administration & dosage
  • Octreotide / adverse effects
  • Octreotide / analogs & derivatives*
  • Octreotide / pharmacokinetics*
  • Pentetic Acid / administration & dosage
  • Pentetic Acid / adverse effects
  • Pentetic Acid / analogs & derivatives*
  • Pentetic Acid / pharmacokinetics*
  • Radiopharmaceuticals / administration & dosage
  • Radiopharmaceuticals / adverse effects
  • Radiopharmaceuticals / pharmacokinetics*

Substances

  • Radiopharmaceuticals
  • SDZ 215-811
  • Pentetic Acid
  • Octreotide